2026-06-22
China approves the world's first CAR-T for a solid tumor
On 2026-06-22 China's NMPA approved satri-cel for pretreated CLDN18.2-positive, HER2-negative advanced gastric/GEJ cancer — the world's first CAR-T approval for a solid tumor. Pivotal data: median PFS 3.25 vs 1.77 months on physician's choice (Lancet 2025). Blood-cancer options are unchanged; the signal is how far ahead of other regulators the NMPA now moves.
What happened
China’s National Medical Products Administration approved satricabtagene autoleucel (satri-cel, CARsgen Therapeutics) for adults with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma whose disease progressed after at least two prior lines of therapy. It is the first CAR-T product approved anywhere in the world for a solid tumor.
The approval rests on the randomized phase 2 trial CT041-ST-01 (NCT04581473), published in The Lancet in 2025: median progression-free survival of 3.25 months on satri-cel versus 1.77 months on treatment of physician’s choice (HR 0.37). Grade 3 or higher treatment-emergent adverse events occurred in 99% of the satri-cel group — mostly cytopenias — and 95% experienced cytokine release syndrome, consistent with CAR-T’s known profile.
Why it matters for international patients
Directly, it does not: this is a gastric-cancer product, and Kaimen’s coverage is CAR-T for blood cancers. Eligibility also requires confirmed CLDN18.2 positivity and two failed prior lines — a narrow, later-line indication.
The signal is regulatory. The NMPA approved a first-in-world cell therapy before the FDA or EMA — a pattern that already applies to several blood-cancer CAR-Ts available commercially in China years before equivalent Western approvals. For patients weighing China, the approval system itself is no longer the question; product-level evidence and center experience are.